HRTX Q3 2019 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HRTXHeron Therapeutics, Inc.

$153M

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$43M+115.4% YoY

Gross Profit

$25M59.7% margin

Operating Income

-$35M-81.8% margin

Net Income

-$34M-78.8% margin

EPS (Diluted)

$-0.42

QoQ Revenue Growth

+16.3%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$24M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$393M

Total Liabilities

$108M

Stockholders' Equity

$285M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$43M	$20M	+115.4%
Gross Profit	$25M	$12M	+108.3%
Operating Income	-$35M	-$42M	+16.6%
Net Income	-$34M	-$38M	+12.4%

Revenue Segments

C I N V A N T I

$36M85%

S U S T O L

$6M15%